\-\ Texto\\:\\ \ \(0\)\
\-\ pertinant\\ positives\\:\\ subtle\\ left\\ facial\\ droop\ \(0\)\
\-\ the\\ initial\\ treatment\\ of\\ choice\\ for\\ glioblastoma\\ multiforme\\ is\\ surgical\\ resection\\ with\\ maximal\\ preservation\\ of\\ neurological\\ function\\.\\ however\\,\\ few\\ if\\ any\\ patients\\ are\\ cured\\ with\\ surgery\\ alone\\.\\ therefore\\,\\ adjuvant\\ focal\\ external\\ beam\\ radiation\\ therapy\\ along\\ with\\ chemotherapy\\ is\\ usually\\ added\\.\\ the\\ median\\ survival\\ rate\\ with\\ supportive\\ care\\ is\\ 14wks\\,\\ 20wks\\ with\\ resectionn\\ alone\\,\\ 36wks\\ for\\ surgery\\ with\\ radiation\\ therapy\\,\\ and\\ 40\\-50wks\\ with\\ the\\ addition\\ of\\ chemotherapy\\.\ \(0\)\
\-\ 4cm\\ hypervascular\\ rim\\ located\\ in\\ the\\ right\\ parietal\\ region\ \(1\)\
\-\ glioblastoma\\ multiforme\ \(8\)\
\-\ primary\\ central\\ nervous\\ system\\ lymphoma\ \(0\)\
\-\ brain\\ metastases\ \(1\)\
\-\ brain\\ abscess\ \(13\)\
\-\ cerebral\\ infarction\ \(29\)\
\-\ hemorrhagic\\ vascular\\ disease\ \(0\)\
\-\ multiple\\ sclerosis\ \(41\)\
\-\ cysticercosis\ \(25\)\
\-\ patient\\ with\\ history\\ of\\ hypertension\\,\\ osteoarthritis\\ and\\ hyperlipidemia\\ presents\\ with\\ one\\ month\\ history\\ of\\ gait\\ disturbance\\,\\ requiring\\ cane\\.\\ progresses\\ to\\ left\\ facial\\ droop\\ and\\ left\\ lower\\ extremity\\ weakness\\.\ \(0\)\
\-\ glioblastoma\\ multiformes\\ are\\ cns\\ neoplasms\\ derived\\ from\\ immortalized\\ astrocytes\\.\\ they\\ occur\\ in\\ all\\ ages\\ with\\ peak\\ at\\ 65\\-75\\ years\\ of\\ age\\.\\ the\\ are\\ more\\ common\\ in\\ men\\ \\(men\\ \\>\\ women\\ 3\\:2\\)\\,\\ and\\ more\\ common\\ in\\ whites\\.\\ the\\ most\\ common\\ presenting\\ symptom\\ is\\ headache\\,\\ followed\\ by\\ memory\\ loss\\,\\ motor\\ weakness\\,\\ visual\\ symptoms\\,\\ language\\ deficit\\,\\ and\\ cognitive\\/personality\\ changes\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ glioblastoma\\:\\ 0\\.24218446435302501\ \(0\)\
\-\ droop\\:\\ 0\\.19356863581266343\ \(0\)\
\-\ multiforme\\:\\ 0\\.16872040773815278\ \(0\)\
\-\ men\\:\\ 0\\.1648565995042686\ \(0\)\
\-\ alone\\:\\ 0\\.15925499201860432\ \(0\)\
\-\ with\\:\\ 0\\.15851575089846798\ \(0\)\
\-\ common\\:\\ 0\\.13772857164493327\ \(0\)\
\-\ facial\\:\\ 0\\.13350344164628664\ \(0\)\
\-\ pertinant\\:\\ 0\\.1294611897981921\ \(0\)\
\-\ 14wks\\:\\ 0\\.1294611897981921\ \(0\)\
\-\ 20wks\\:\\ 0\\.1294611897981921\ \(0\)\
\-\ resectionn\\:\\ 0\\.1294611897981921\ \(0\)\
\-\ 36wks\\:\\ 0\\.1294611897981921\ \(0\)\
\-\ multiformes\\:\\ 0\\.1294611897981921\ \(0\)\
\-\ immortalized\\:\\ 0\\.1294611897981921\ \(0\)\
\-\ astrocytes\\:\\ 0\\.1237070782847532\ \(0\)\
\-\ weakness\\:\\ 0\\.11816251479444255\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.11496372201563639\ \(0\)\
\-\ positives\\:\\ 0\\.11168274801250314\ \(0\)\
\-\ language\\:\\ 0\\.1097877525903537\ \(0\)\
\-\ radiation\\:\\ 0\\.10729213367313106\ \(0\)\
\-\ cured\\:\\ 0\\.10662103651025091\ \(0\)\
\-\ cane\\:\\ 0\\.10662103651025091\ \(0\)\
\-\ whites\\:\\ 0\\.10526845304007548\ \(0\)\
\-\ brain\\:\\ 0\\.10093155395437857\ \(0\)\
\-\ disturbance\\:\\ 0\\.0999510339864345\ \(0\)\
\-\ derived\\:\\ 0\\.09909068662875566\ \(0\)\
\-\ added\\:\\ 0\\.0982795295634759\ \(0\)\
\-\ the\\:\\ 0\\.09691813067564012\ \(0\)\
\-\ of\\:\\ 0\\.09505265659941244\ \(0\)\
\-\ beam\\:\\ 0\\.09480090235298416\ \(0\)\
\-\ progresses\\:\\ 0\\.09480090235298416\ \(0\)\
\-\ adjuvant\\:\\ 0\\.0941969224729956\ \(0\)\
\-\ nervous\\:\\ 0\\.0941969224729956\ \(0\)\
\-\ memory\\:\\ 0\\.0941969224729956\ \(0\)\
\-\ therapy\\:\\ 0\\.0930252960166295\ \(0\)\
\-\ maximal\\:\\ 0\\.09252541805003701\ \(0\)\
\-\ are\\:\\ 0\\.09215374551389355\ \(0\)\
\-\ cysticercosis\\:\\ 0\\.08925396802483646\ \(0\)\
\-\ more\\:\\ 0\\.0889035182686721\ \(0\)\
\-\ hyperlipidemia\\:\\ 0\\.08884259472456195\ \(0\)\
\-\ is\\:\\ 0\\.08867792389346633\ \(0\)\
\-\ preservation\\:\\ 0\\.08844281095955671\ \(0\)\
\-\ surgery\\:\\ 0\\.08704732477815569\ \(0\)\
\-\ hypervascular\\:\\ 0\\.08559501583223708\ \(0\)\
\-\ 4cm\\:\\ 0\\.08527609487945392\ \(0\)\
\-\ median\\:\\ 0\\.08378088322230973\ \(0\)\
\-\ and\\:\\ 0\\.08363955036783799\ \(0\)\
\-\ peak\\:\\ 0\\.08295396670494015\ \(0\)\
\-\ left\\:\\ 0\\.08284432201765315\ \(0\)\
\-\ ages\\:\\ 0\\.08268869944611781\ \(0\)\
\-\ symptom\\:\\ 0\\.0824282997521343\ \(0\)\
\-\ requiring\\:\\ 0\\.08072815478434166\ \(0\)\
\-\ in\\:\\ 0\\.0805537418970191\ \(0\)\
\-\ survival\\:\\ 0\\.07900587612064275\ \(0\)\
\-\ choice\\:\\ 0\\.0767604583229008\ \(0\)\
\-\ deficit\\:\\ 0\\.07658843942706252\ \(0\)\
\-\ cns\\:\\ 0\\.07559794088770261\ \(0\)\
\-\ neoplasms\\:\\ 0\\.07543937627553472\ \(0\)\
\-\ osteoarthritis\\:\\ 0\\.07394416461839053\ \(0\)\
\-\ women\\:\\ 0\\.07285198084219861\ \(0\)\
\-\ therefore\\:\\ 0\\.07135676918505442\ \(0\)\
\-\ hemorrhagic\\:\\ 0\\.07022085229213092\ \(0\)\
\-\ gait\\:\\ 0\\.07011210551365464\ \(0\)\
\-\ subtle\\:\\ 0\\.06979077740538298\ \(0\)\
\-\ visual\\:\\ 0\\.0690681507903336\ \(0\)\
\-\ few\\:\\ 0\\.0686711630819128\ \(0\)\
\-\ supportive\\:\\ 0\\.06763345685879481\ \(0\)\
\-\ neurological\\:\\ 0\\.0664975399658713\ \(0\)\
\-\ function\\:\\ 0\\.06552403483811303\ \(0\)\
\-\ addition\\:\\ 0\\.06552403483811303\ \(0\)\
\-\ external\\:\\ 0\\.06544584519046391\ \(0\)\
\-\ metastases\\:\\ 0\\.06544584519046391\ \(0\)\
\-\ parietal\\:\\ 0\\.06536808398139013\ \(0\)\
\-\ rim\\:\\ 0\\.06446674077869201\ \(0\)\
\-\ motor\\:\\ 0\\.06439415041505656\ \(0\)\
\-\ located\\:\\ 0\\.06403666589194407\ \(0\)\
\-\ infarction\\:\\ 0\\.06355084976831449\ \(0\)\
\-\ presenting\\:\\ 0\\.06341504600328465\ \(0\)\
\-\ hypertension\\:\\ 0\\.061940122248306924\ \(0\)\
\-\ history\\:\\ 0\\.061857330725627484\ \(0\)\
\-\ system\\:\\ 0\\.061758566870399295\ \(0\)\
\-\ rate\\:\\ 0\\.061343757815320824\ \(0\)\
\-\ occur\\:\\ 0\\.05953663502778765\ \(0\)\
\-\ extremity\\:\\ 0\\.05830610855013394\ \(0\)\
\-\ care\\:\\ 0\\.05784229651277728\ \(0\)\
\-\ they\\:\\ 0\\.05784229651277728\ \(0\)\
\-\ sclerosis\\:\\ 0\\.057660934489845744\ \(0\)\
\-\ cerebral\\:\\ 0\\.05608486002047948\ \(0\)\
\-\ headache\\:\\ 0\\.055805414434313916\ \(0\)\
\-\ followed\\:\\ 0\\.05466645707321627\ \(0\)\
\-\ initial\\:\\ 0\\.05430625029555428\ \(0\)\
\-\ along\\:\\ 0\\.05423529322198433\ \(0\)\
\-\ central\\:\\ 0\\.054059437376326624\ \(0\)\
\-\ vascular\\:\\ 0\\.05344381089318255\ \(0\)\
\-\ any\\:\\ 0\\.05231819627668136\ \(0\)\
\-\ abscess\\:\\ 0\\.051982109015831314\ \(0\)\
\-\ resection\\:\\ 0\\.051891813577706294\ \(0\)\
\-\ usually\\:\\ 0\\.05096280235295709\ \(0\)\
\-\ age\\:\\ 0\\.050822984619537166\ \(0\)\
\-\ primary\\:\\ 0\\.049777253864032034\ \(0\)\
\-\ years\\:\\ 0\\.04962299815888024\ \(0\)\
\-\ loss\\:\\ 0\\.04931942754307074\ \(0\)\
\-\ month\\:\\ 0\\.049244538793302074\ \(0\)\
\-\ for\\:\\ 0\\.049072359615693256\ \(0\)\
\-\ changes\\:\\ 0\\.04892451134290434\ \(0\)\
\-\ focal\\:\\ 0\\.04842232063225699\ \(0\)\
\-\ region\\:\\ 0\\.04842232063225699\ \(0\)\
\-\ lymphoma\\:\\ 0\\.04821241957264869\ \(0\)\
\-\ all\\:\\ 0\\.048189287725394325\ \(0\)\
\-\ however\\:\\ 0\\.047914607179729216\ \(0\)\
\-\ if\\:\\ 0\\.04703560272554413\ \(0\)\
\-\ one\\:\\ 0\\.04634929213094883\ \(0\)\
\-\ patients\\:\\ 0\\.04554039106839993\ \(0\)\
\-\ symptoms\\:\\ 0\\.044292799829140674\ \(0\)\
\-\ most\\:\\ 0\\.04213030121841346\ \(0\)\
\-\ lower\\:\\ 0\\.041366981742620476\ \(0\)\
\-\ multiple\\:\\ 0\\.03959578830357156\ \(0\)\
\-\ surgical\\:\\ 0\\.039345713371883036\ \(0\)\
\-\ presents\\:\\ 0\\.038942487184750914\ \(0\)\
\-\ treatment\\:\\ 0\\.038562125786179284\ \(0\)\
\-\ by\\:\\ 0\\.034377264320167744\ \(0\)\
\-\ disease\\:\\ 0\\.03398111983846197\ \(0\)\
\-\ from\\:\\ 0\\.032151029833598035\ \(0\)\
\-\ at\\:\\ 0\\.030576906635683108\ \(0\)\
\-\ right\\:\\ 0\\.026839210800476344\ \(0\)\
\-\ patient\\:\\ 0\\.026329889874199104\ \(0\)\
\-\ to\\:\\ 0\\.020238047100167363\ \(0\)\
